Clinical Trial Update: Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)

View source ↗

Summary

A completed clinical trial assessed the effectiveness and tolerability of agomelatine for depression after SARS-CoV-2 infection. Results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Valdoxan (agomelatine)

Snippet

Sponsor: Servier Russia | Conditions: Depression, COVID-19 | Status: COMPLETED | Results posted: 2024-10-17